Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas

Amir Behdad; Nathanael G. Bailey

doi:10.1016/j.path.2015.09.008

Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas

Amir Behdad^*, Nathanael G. Bailey

^*Corresponding author for this work

Pathology

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

High-grade B-cell lymphomas (HGBCLs) are a heterogeneous group of neoplasms that include subsets of diffuse large B-cell lymphoma, Burkitt lymphoma, and lymphomas with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Morphologically indistinguishable HGBCLs may demonstrate variable clinical courses and responses to therapy. The morphologic evaluation and classification of these neoplasms must be followed by further genetic and immunophenotypic work-up. These additional diagnostic modalities lead to a comprehensive stratification of HGBCL that determines the prognosis and optimal therapy. This article reviews the well-established and emerging biomarkers that are most relevant to the clinical management of HGBCL.

Original language	English (US)
Pages (from-to)	41-54
Number of pages	14
Journal	Surgical Pathology Clinics
Volume	9
Issue number	1
DOIs	https://doi.org/10.1016/j.path.2015.09.008
State	Published - Mar 1 2016

Keywords

Burkitt lymphoma
Cell of origin
Diffuse large B-cell lymphoma
MYC

ASJC Scopus subject areas

Surgery
Pathology and Forensic Medicine

Access to Document

10.1016/j.path.2015.09.008

Cite this

@article{da97c63c53ee42cda42593fc4e87bb08,

title = "Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas",

abstract = "High-grade B-cell lymphomas (HGBCLs) are a heterogeneous group of neoplasms that include subsets of diffuse large B-cell lymphoma, Burkitt lymphoma, and lymphomas with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Morphologically indistinguishable HGBCLs may demonstrate variable clinical courses and responses to therapy. The morphologic evaluation and classification of these neoplasms must be followed by further genetic and immunophenotypic work-up. These additional diagnostic modalities lead to a comprehensive stratification of HGBCL that determines the prognosis and optimal therapy. This article reviews the well-established and emerging biomarkers that are most relevant to the clinical management of HGBCL.",

keywords = "Burkitt lymphoma, Cell of origin, Diffuse large B-cell lymphoma, MYC",

author = "Amir Behdad and Bailey, {Nathanael G.}",

year = "2016",

month = mar,

day = "1",

doi = "10.1016/j.path.2015.09.008",

language = "English (US)",

volume = "9",

pages = "41--54",

journal = "Surgical Pathology Clinics",

issn = "1875-9181",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas

AU - Behdad, Amir

AU - Bailey, Nathanael G.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - High-grade B-cell lymphomas (HGBCLs) are a heterogeneous group of neoplasms that include subsets of diffuse large B-cell lymphoma, Burkitt lymphoma, and lymphomas with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Morphologically indistinguishable HGBCLs may demonstrate variable clinical courses and responses to therapy. The morphologic evaluation and classification of these neoplasms must be followed by further genetic and immunophenotypic work-up. These additional diagnostic modalities lead to a comprehensive stratification of HGBCL that determines the prognosis and optimal therapy. This article reviews the well-established and emerging biomarkers that are most relevant to the clinical management of HGBCL.

AB - High-grade B-cell lymphomas (HGBCLs) are a heterogeneous group of neoplasms that include subsets of diffuse large B-cell lymphoma, Burkitt lymphoma, and lymphomas with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Morphologically indistinguishable HGBCLs may demonstrate variable clinical courses and responses to therapy. The morphologic evaluation and classification of these neoplasms must be followed by further genetic and immunophenotypic work-up. These additional diagnostic modalities lead to a comprehensive stratification of HGBCL that determines the prognosis and optimal therapy. This article reviews the well-established and emerging biomarkers that are most relevant to the clinical management of HGBCL.

KW - Burkitt lymphoma

KW - Cell of origin

KW - Diffuse large B-cell lymphoma

KW - MYC

UR - http://www.scopus.com/inward/record.url?scp=84959200271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959200271&partnerID=8YFLogxK

U2 - 10.1016/j.path.2015.09.008

DO - 10.1016/j.path.2015.09.008

M3 - Review article

C2 - 26940267

AN - SCOPUS:84959200271

SN - 1875-9181

VL - 9

SP - 41

EP - 54

JO - Surgical Pathology Clinics

JF - Surgical Pathology Clinics

IS - 1

ER -

Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this